|本期目录/Table of Contents|

[1]中华医学会肝病学分会脂肪肝和酒精性肝病学组中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018 更新版)[J].传染病信息,2018,05:393-402.
 National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association Fatty Liver Expert Committee,et al.Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update[J].Infectious Disease Information,2018,05:393-402.
点击复制

非酒精性脂肪性肝病防治指南(2018 更新版)(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2018年05期
页码:
393-402
栏目:
特别报道
出版日期:
2018-10-30

文章信息/Info

Title:
Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update
作者:
中华医学会肝病学分会脂肪肝和酒精性肝病学组中国医师协会脂肪性肝病专家委员会 
Author(s):
National Workshop on Fatty Liver and Alcoholic Liver Disease Chinese Society of Hepatology Chinese Medical Association Fatty Liver Expert Committee Chinese Medical Doctor Association
关键词:
脂肪肝诊断治疗代谢综合征指南
Keywords:
fatty liver diagnosis therapy metabolic syndrome guidebooks
分类号:
R575
DOI:
10.3969/j.issn.1007-8134.2018.05.002
文献标识码:
A
摘要:
-
Abstract:
-

参考文献/References


[1] Rinella ME. Nonalcoholic fatty liver disease:a systematic review[J].JAMA, 2015, 313(22):2263-2273. DOI: 10.1001/jama.2015.5370.
[2] Diehl AM, Day C. Cause, pathogenesis, and treatment ofnonalcoholic steatohepatitis[J]. N Engl J Med, 2017,377(21):2063-2073. DOI: 10.1056/NEJMra1503519.
[3] Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease:the major impact of China[J]. Hepatology, 2014, 60(6):2099-2108. DOI: 10.1002/hep.27406.
[4] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLDin Asia[J]. J Hepatol, 2017, 67(4):862-873. DOI: 10.1016/j.jhep.2017.06.003.
[5] Wang MM, Wang GS, Shen F, et al. Hepatic steatosis is highlyprevalent in hepatitis B patients and negatively associated withvirological factors[J]. Dig Dis Sci, 2014, 59(10):2571-2579.DOI: 10.1007/s10620-014-3180-9.
[6] Fan JG, Jia JD, Li YM, et al. Guidelines for the diagnosisand management of nonalcoholic fatty liver disease:update2010:(published in Chinese on Chinese Journal of Hepatology 2010;18:163-166)[J]. J Dig Dis, 2011, 12(1):38-44. DOI: 10.1111/j.1751-2980.2010.00476.x.
[7] Review Team, LaBrecque DR, Abbas Z, et al. WorldGastroenterology Organisation global guideline: Nonalcoholicfatty liver disease and nonalcoholic steatohepatitis[J].J Clin Gastroenterol, 2014, 48(6):467-473. DOI: 10.1097/MCG.0000000000000116.
[8] Wong VW, Chan WK, Chitturi S, et al. Asia-Pacific WorkingParty on Non-alcoholic Fatty Liver Disease Guidelines 2017-Part1: Definition, risk factors and assessment[J]. J GastroenterolHepatol, 2018, 33(1):70-85. DOI: 10.1111/jgh.13857.
[9] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis andmanagement of nonalcoholic fatty liver disease: practice guidancefrom the American Association for the Study of Liver Diseases[J].Hepatology, 2018, 67(1):328-357. DOI: 10.1002/hep.29367.
[10] European Association for the Study of the Liver, EuropeanAssociation for the Study of Diabetes, European Association for theStudy of Obesity. Clinical Practice Guidelines for the managementof non-alcoholic fatty liver disease[J]. J Hepatol, 2016,64(6):1388-1402.
[11] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiologyof nonalcoholic fatty liver disease-Meta-analytic assessment ofprevalence, incidence, and outcomes[J]. Hepatology, 2016,64(1):73-84. DOI: 10.1002/hep.28431.
[12] Zhu JZ, Zhou QY, Wang YM, et al. Prevalence of fatty liver diseaseand the economy in China: A systematic review[J]. World JGastroenterol, 2015, 21(18):5695-5706.DOI: 10.3748/wjg.v21.i18.5695.
[13] Wong VW, Wong GL, Yeung DK, et al.Incidence of non-alcoholicfatty liver disease in Hong Kong: a population study with pairedproton-magnetic resonance spectroscopy[J]. J Hepatol, 2015,62(1):182-189. DOI: 10.1016/j.jhep.2014.08.041.
[14] Xu C, Yu C, Ma H, et al. Prevalence and risk factors for thedevelopment of nonalcoholic fatty liver disease in a nonobeseChinese population: the Zhejiang Zhenhai Study[J].AmJ Gastroenterol, 2013, 108(8):1299-1304. DOI: 10.1038/ajg.2013.104.
[15] Kwok R, Choi KC, Wong GL, et al. Screening diabetic patientsfor non-alcoholic fatty liver disease with controlled attenuationparameter and liver stiffness measurements:a prospective cohortstudy[J]. Gut, 2016, 65(8):1359-1368. DOI: 10.1136/gutjnl-2015-309265.
[16] Zhang RN, Zheng RD, Mi YQ, et al. APOC3 rs2070666 is associatedwith the hepatic steatosis independently of PNPLA3 rs738409 inChinese Han patients with nonalcoholic fatty liver diseases[J].Dig Dis Sci, 2016, 61(8):2284-2293. DOI: 10.1007/s10620-016-4120-4127.
[17] Xu L, Ma H, Miao M, et al. Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease:a prospectivecase-control study[J]. J Hepatol, 2012, 57(5):1153-1154. DOI:10.1016/j.jhep.2012.05.025.
[18] Xu C, Yu C, Xu L, et al. High serum uric acid increases the riskfor nonalcoholic Fatty liver disease: a prospective observationalstudy[J]. PLoS One, 2010, 5(7):e11578. DOI: 10.1371/journal.pone.0011578.
[19] Ma H, Xu C, Xu L, et al. Independent association of HbA1c andnonalcoholic fatty liver disease in an elderly Chinese population[J].BMC Gastroenterol, 2013, 13:3. DOI: 10.1186/1471-230X-13-3.
[20] Xu C, Wan X, Xu L, et al. Xanthine oxidase in non-alcoholic fattyliver disease and hyperuricemia: One stone hits two birds[J]. JHepatol, 2015, 62(6):1412-1419. DOI: 10.1016/j.jhep.2015.01.019.
[21] Dulai PS, Singh S, Patel J, et al. Increased risk of mortality byfibrosis stage in nonalcoholic fatty liver disease: Systematic reviewand meta-analysis[J]. Hepatology, 2017, 65(5):1557-1565. DOI:10.1002/hep.29085.
[22] Leung JC, Loong TC, Wei JL, et al. Histological severity and clinicaloutcomes of nonalcoholic fatty liver disease in nonobese patient[s J].Hepatology, 2017, 65(1):54-64.DOI: 10.1002/hep.28697.
[23] Wang Y, Wang B, Shen F, et al.Body mass index and risk ofprimary liver cancer:a meta-analysis of prospective studies [J]. Oncologist, 2012, 17(11):1461-1468.DOI: 10.1634/theoncologist.2012-0066.
[24] Wong VW, Wong GL, Yeung JC, et al. Long-term clinical outcomesafter fatty liver screening in patients undergoing coronary angiogram:A prospective cohort study[J]. Hepatology, 2016, 63(3):754-763.DOI: 10.1002/hep.28253.
[25] Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver diseaseis associated with an almost twofold increased risk of incident type2 diabetes and metabolic syndrome. Evidence from a systematicreview and meta-analysis[J]. J Gastroenterol Hepatol, 2016,31(5):936-944. DOI: 10.1111/jgh.13264.
[26] Chen GY, Cao HX, Li F, et al. New-risk-scoring system includingnon-alcoholic fatty liver disease for predicting incident type 2diabetes in East China:Shanghai Baosteel Cohort[J]. J DiabetesInvestig, 2016, 7(2):206-211. DOI: 10.1111/jdi.12395.
[27] Wu S, Wu F, Ding Y, et al. Association of non-alcoholic fatty liverdisease with major adverse cardiovascular events: A systematicreview and meta-analysis[J]. Sci Rep, 2016, 6:33386. DOI:10.1038/srep33386.
[28] Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liverdisease and risk of incident cardiovascular disease:A metaanalysis[J]. J Hepatol, 2016, 65(3):589-600. DOI: 10.1016/j.jhep.2016.05.013.
[29] Wu R, Hou F, Wang X, et al. Nonalcoholic fatty liver disease andcoronary artery calcification in a northern Chinese population:a cross sectional study[J]. Sci Rep, 2017, 7(1):9933. DOI:10.1038/s41598-017-09851-5.
[30] Musso G, Gambino R, Tabibian JH, et al.Association of nonalcoholicfatty liver disease with chronic kidney disease:a systematicreview and meta-analysis[J]. PLoS Med, 2014, 11(7):e1001680.DOI: 10.1371/journal.pmed.1001680.
[31] Zeng J, Sun C, Sun WL, et al. Association between non-invasivelydiagnosed hepatic steatosis and chronic kidney disease in Chineseadults at a health check-up[J]. J Dig Dis, 2017, 18(4):229-236.DOI: 10.1111/1751-2980.12465.
[32] Ding W, Fan J, Qin J. Association between nonalcoholic fatty liverdisease and colorectal adenoma: a systematic review and metaanalysis[J]. Int J Clin Exp Med, 2015, 8(1):322-333.
[33] Chitturi S, Wong VW, Chan WK, et al. The Asia-Pacific WorkingParty on Non-alcoholic Fatty Liver Disease guidelines 2017-Part2: Management and special groups[J]. J Gastroenterol Hepatol,2018, 33(1):86-98. DOI: 10.1111/jgh.13856.

备注/Memo

备注/Memo:

[ 通信作者] 范建高,上海交通大学医学院附属新华医院消化 内科,E-mail: fattyliver2004@126.com;魏来,北京大学人民医院, 北京大学肝病研究所,E-mail: weilai@pkuph.edu.cn;庄辉,北京 大学医学部,E-mail: zhuangbmu@126.com
更新日期/Last Update: 2018-10-30